SLC5A2 and endothelial dysfunction: Secondly, treatment with the SGLT2 inhibitor DAPA leads to significantly less weight gain, promotes BP lowering, protects against endothelial dysfunction, stimulates beneficial changes in the gut microbiome and decreases markers of SNS innervation and activity (Fig. 4).